Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA approvals

This article was originally published in The Tan Sheet

Executive Summary

Alpharma receives FDA clearance for private label permethrin lotion 1% (ANDA 75-014) on March 28. The product is the first approved generic version of Warner-Lambert's Nix pediculicide, the company says. Alpharma plans to launch the private label product April 1 in 60 mL bottles in single-, double- and triple-packs. Pfizer's Rid, which contains pyrethrum extract, was extended with a mousse delivery form approved March 7 under an "NDA Deviation" (1"The Tan Sheet" March 13, p. 4). Cheminor also receive ANDA approval March 28 for a generic version of a Warner product. The company's ranitidine 75 mg tablets (ANDA 75-294) will compete with the W-L reference drug, Zantac 75; the H2 antagonist lost its marketing exclusivity last June
Advertisement

Related Content

Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"

Topics

Advertisement
UsernamePublicRestriction

Register

PS091029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel